Portfolio company Minoryx Therapeutics' NEZGLYAL (leriglitazone) received a positive CHMP opinion for treating cerebral adrenoleukodystrophy, a rare neurodegenerative disease.
Minoryx Therapeutics is a clinical stage biotech company focused on the discovery and development of innovative treatments for orphan CNS diseases, particularly X-linked Adrenoleukodystrophy (X-ALD) and other severe neurodegenerative disorders
Minoryx Therapeutics is a clinical stage biotech company focused on the discovery and development of innovative treatments for orphan CNS diseases, particularly X-linked Adrenoleukodystrophy (X-ALD) and other severe neurodegenerative disorders.